Bilman Victor, Cambiaghi Tommaso, Grandi Alessandro, Carta Niccolò, Melissano Germano, Chiesa Roberto, Bertoglio Luca
Cirurgia Vascular e Endovascular, Pontifícia Universidade Católica do Rio de Janeiro - PUC-Rio, Rio de Janeiro, RJ, Brazil.
Department of Cardiothoracic and Vascular Surgery, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.
Eur J Cardiothorac Surg. 2020 Dec 1;58(6):1296-1303. doi: 10.1093/ejcts/ezaa276.
The aim of this study was to evaluate the proportion of thoraco-abdominal aortic aneurysms (TAAAs) that could theoretically be treated with the JOTEC® E-nside® Thoracoabdominal Branch Endoprosthesis off-the-shelf multibranched endograft.
Preoperative computed tomography scans of patients with atherosclerotic TAAA treated between 2007 and 2019 were reviewed, and the anatomical feasibility of the E-nside graft was verified by a retrospective study (clinicaltrials.gov: NCT03959670) based on the investigational manufacturer instructions for use. The anatomical factors determining overall feasibility were divided into vascular access (AC) feasibility, aortic (AO) feasibility and visceral vessels (VV) feasibility.
Two hundred sixty-eight patients with thoraco-abdominal aneurysms were analysed: the overall treatment feasibility was 43%. AC feasibility was 78%, AO feasibility 60% and VV feasibility 79%. An iliac diameter <8.5 mm excluded 21% of the patients. Aortic feasibility was limited by infrarenal aortic diameter (16%) and size of aortic lumen at the level of visceral vessels (14%). Visceral vessels feasibility was mainly limited by inadequate number (8%) or diameter (12%) of target vessels. Height and orientation of target vessels were adequate in 97% of the cases. Overall feasibility was negatively influenced by female gender (Odds ratio: 3.89; 95% confidence interval 2.03-7.44; P < 0.001): the limiting factors in this subgroup being iliac diameter, infrarenal aortic diameter and visceral vessels diameter.
The E-nside off-the-shelf stent graft can be theoretically employed in almost half of the cases from an all-comers cohort of patients with TAAA. Improvement of device profile and creation of a dedicated infrarenal component are warranted to increase overall feasibility. Female gender significantly affects the overall feasibility.
CLINICALTRIALS.GOV: NCT03959670.
本研究旨在评估理论上可使用JOTEC® E-nside®胸主动脉腹主动脉分支型人工血管(现成的多分支血管内移植物)治疗的胸腹主动脉瘤(TAAA)的比例。
回顾性分析2007年至2019年期间接受治疗的动脉粥样硬化性TAAA患者的术前计算机断层扫描,并根据研究制造商的使用说明,通过一项回顾性研究(clinicaltrials.gov:NCT03959670)验证E-nside移植物的解剖学可行性。将决定总体可行性的解剖学因素分为血管入路(AC)可行性、主动脉(AO)可行性和内脏血管(VV)可行性。
对268例胸腹主动脉瘤患者进行了分析:总体治疗可行性为43%。AC可行性为78%,AO可行性为60%,VV可行性为79%。髂动脉直径<8.5mm排除了21%的患者。主动脉可行性受肾下腹主动脉直径(16%)和内脏血管水平主动脉腔大小(14%)的限制。内脏血管可行性主要受目标血管数量不足(8%)或直径(12%)的限制。97%的病例中目标血管的高度和方向合适。总体可行性受到女性性别负面影响(优势比:3.89;95%置信区间2.03 - 7.44;P < 0.001):该亚组中的限制因素为髂动脉直径、肾下腹主动脉直径和内脏血管直径。
理论上,E-nside现成的支架型人工血管可用于几乎一半来自所有TAAA患者队列的病例。有必要改进器械外形并创建专用的肾下组件以提高总体可行性。女性性别显著影响总体可行性。
NCT03959670